Novel 18F-labeled radiohybrid (rh) PET radiopharmaceutical, 18F-rhPSMA-7.3 (18F-flotufolastat), is a newly FDA-approved high-affinity PSMA-targeting diagnostic for patients with prostate cancer. Here, FOLH1 is linked to prostate cancer.